Evidence mapPaperPMID 33762313Full record

ReviewBMJ open diabetes research & care2021

Glycemic variability and cardiovascular disease in patients with type 2 diabetes.

Marcela Martinez, Jimena Santamarina, Adrian Pavesi, Carla Musso, Guillermo E Umpierrez

Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in BMJ open diabetes research & care, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06243536 (The Effect of Semaglutide on Disordered Eating Behaviour in Type 2 Diabetic Patients), which is not on this map. Cited by 82 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
82citing papers in PubMed, 1 pooled it
13.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06243536 phase4unknown statusstarted 2024, after this paper: background citation

The Effect of Semaglutide on Disordered Eating Behaviour in Type 2 Diabetic Patients

Ran2024Enrolled60Registered outcomes3Posted comparisons0ConditionsDisordered Eating Behaviors, Overweight, Type 2 DiabetesArmssemaglutide, Standard of care
Open the trial in the graph
3 · Its place in the literature

Who cites it

82 citing papers in PubMed, 1 synthesis or guideline pooled it, 143 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Time-restricted eating to address persistent cancer-related fatigue among cancer survivors: a randomized controlled trial.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Trial
  4. Trial
  5. Trial
  6. Trial
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Decoding the coronary paradox of obesity: not all fat is equal!International journal of cardiology. Heart & vasculature · 2025
    Article
  17. Article
  18. Review
  19. Article
  20. Article

22 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Marcela MartinezDiabetes and Metabolism, Favaloro Foundation University Hospital, Buenos Aires, Federal District, Argentina.
Jimena SantamarinaDiabetes and Metabolism, Favaloro Foundation University Hospital, Buenos Aires, Federal District, Argentina.
Adrian PavesiDiabetes and Endocrinology, Favaloro Foundation University Hospital, Buenos Aires, Federal District, Argentina.
Carla MussoDiabetes and Endocrinology, Favaloro Foundation University Hospital, Buenos Aires, Federal District, Argentina.
Guillermo E UmpierrezMedicine, Emory University, Atlanta, Georgia, USA geumpie@emory.edu.ORCID 0000-0002-3252-5026
Favaloro Foundation · AREmory University · US

Funding

Georgia Clinical & Translational Science Alliance (Georgia CTSA)UL1TR002378 · EMORY UNIVERSITY · 2025 to 2025
$9.3M
NCATS NIH HHS UL1 TR002378
6 · The paper itself

Abstract

Glycated hemoglobin is currently the gold standard for assessment of long-term glycemic control and response to medical treatment in patients with diabetes. Glycated hemoglobin, however, does not address fluctuations in blood glucose. Glycemic variability (GV) refers to fluctuations in blood glucose levels. Recent clinical data indicate that GV is associated with increased risk of hypoglycemia, microvascular and macrovascular complications, and mortality in patients with diabetes, independently of glycated hemoglobin level. The use of continuous glucose monitoring devices has markedly improved the assessment of GV in clinical practice and facilitated the assessment of GV as well as hypoglycemia and hyperglycemia events in patients with diabetes. We review current concepts on the definition and assessment of GV and its association with cardiovascular complications in patients with type 2 diabetes.

Indexed as

Cardiovascular DiseasesDiabetes Mellitus, Type 2Blood GlucoseBlood Glucose Self-MonitoringGlycated HemoglobinHumansBlood GlucoseGlycated Hemoglobincardiovascular systemdiabetes mellitusdiagnostic techniques and procedurestype 2

Identifiers

PMID33762313
PMCPMC7993171
OpenAlexW3138553431

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.